NEW YORK, April 4, 2017 /PRNewswire/ --
Companies in the Generic Drugs space develop prescription and over-the-counterdrug products that are used to prevent or treat illnesses in humans or animals. Industry operators are not significantly engaged in the research and development of new drugs, as generic drugs are produced and distributed without patent protection. Pre-market
On Monday, shares in Parsippany, New Jersey headquartered Zoetis Inc. saw a slight decline of 0.37%, ending the day at $53.17. The stock recorded a trading volume of 2.81 million shares. The Company's shares are trading above their 200-day moving average by 3.41%. Moreover, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have a Relative Strength Index (RSI) of 40.29.
On March 31st, 2017, Zoetis announced that the Company will host a webcast and conference call at 8:30 a.m. ET on Thursday, May 04th, 2017. Chief Executive Officer, Juan Ramon Alaix, and Executive Vice President and Chief Financial Officer, Glenn David, will review Q1 2017 financial results and respond to questions from financial analysts during the call. ZTS complete research report is just a click away and free at:
Shares in Chesterfield, the UK-based Mallinckrodt PLC ended the day 1.01% lower at $44.12 with a total trading volume of 1.66 million shares. The stock is trading below its 50-day moving average by 9.74%. Shares of the Company, which develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies in the US, Europe, Middle East, Africa, and internationally, have an RSI of 36.41.
On March 24th, 2017, Mallinckrodt announced that the Company will report Q1 FY17 earnings results for the period of December 31st, 2016, to March 31st, 2017, on Monday, May 08th, 2017. A conference call for investors will begin at 8:30 a.m. ET. The complimentary report on MNK can be downloaded at: http://stock-callers.com/registration/?symbol=MNK
At the close of trading on Monday, shares in Lake Forest, Illinois headquartered Akorn Inc. finished 1.62% lower at $23.69. A total volume of 2.78 million shares was traded, which was above their three months average volume of 1.74 million shares. The stock has advanced 8.52% over the previous three months. The Company's shares are trading above their 50-day moving average by 9.28%. Additionally, shares of Akorn, which develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter drug products, and animal health products in the US and internationally, have an RSI of 58.68.
On March 10th, 2017, research firm WallachBeth reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $22 a share to $25 a share. Sign up for your complimentary research report on AKRX at:
MYOS RENS Technology
Cedar Knolls, New Jersey-based MYOS RENS Technology Inc.'s shares recorded a trading volume of 142,961 shares at the end of yesterday's session. The stock closed the day 2.08% lower at $2.83. The Company's shares have surged 139.83% in the last three months. The stock is trading above its 200-day moving average by 34.41%. Additionally, shares of MYOS RENS Technology, which focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue, have an RSI of 47.33.
On March 31st, 2017, MYOS RENS Technology announced that it will host an interactive conference call on April 04th, 2017 at 11 a.m. ET. Moderated by CEO Joseph Mannello, the call will focus on the launch of the Qurr product-line, and will highlight significant developments of the last seven months. Get free access to your research report on MYOS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!